Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis

Company Overview

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic cell therapies for diseases with significant unmet medical needs. The company uses its cell biology and manufacturing platforms to create specialized cells intended to replace, support or repair damaged tissues.

Lineage’s lead program, OpRegen, is an investigational retinal pigment epithelium cell therapy being developed for geographic atrophy associated with dry age-related macular degeneration. The company is also advancing ANP1, formerly known as OPC1, an allogeneic neural progenitor cell program being studied for potential use in spinal cord injury. Its pipeline has also included cell-based approaches for neurological and oncology indications.

The company was formerly known as BioTime, Inc. and adopted the Lineage Cell Therapeutics name in 2019. Lineage is headquartered in Carlsbad, California, and conducts research and clinical development activities through its operations and collaborators in the United States and internationally. Brian M. Culley serves as the company’s chief executive officer.

Key Stats

• Today's Range: $0.93 to $0.97
• 50-Day Range: $0.90 to $1.16
• 52-Week Range: $0.88 to $2.09
• Volume: 966,920 shs
• Average Volume: 1.63 million shs
• Market Capitalization: $237.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.25
• Consensus Rating: Buy

Lineage Cell Therapeutics Stock Analysis - MarketRank™

Lineage Cell Therapeutics scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Lineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Lineage Cell Therapeutics has a consensus price target of $6.25, representing about 566.4% upside from its current price of $0.94.

Amount of Analyst Coverage

Lineage Cell Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lineage Cell Therapeutics are expected to grow in the coming year, from ($0.07) to ($0.04) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lineage Cell Therapeutics is -4.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lineage Cell Therapeutics is -4.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lineage Cell Therapeutics has a P/B Ratio of 4.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.47% of the float of Lineage Cell Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 26.64, which indicates bearish sentiment.

Change versus previous month

Short interest in Lineage Cell Therapeutics has recently increased by 1.68%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lineage Cell Therapeutics does not currently pay a dividend.

Dividend Growth

Lineage Cell Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Lineage Cell Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for LCTX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

MarketBeat Follows

2 people have added Lineage Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lineage Cell Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.70% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/07/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:LCTX
• CIK: 876343
• Web: www.lineagecell.com
• Phone: (442) 287-8963
• Fax: 510-521-3389
• Employees: 77
• Year Founded: 1990

Price Target and Rating

• Average Price Target for Lineage Cell Therapeutics: $6.25
• High Price Target: $9.00
• Low Price Target: $3.00
• Potential Upside/Downside: +566.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$63.53 million
• Net Margins: -246.58%
• Pretax Margin: -285.75%
• Return on Equity: -73.06%
• Return on Assets: -30.87%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.61
• Quick Ratio: 6.61

Sales & Book Value

• Annual Sales: $14.56 million
• Price / Sales: 16.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.19 per share
• Price / Book: 4.94

Miscellaneous

• Outstanding Shares: 252,910,000
• Free Float: 190,439,000
• Market Cap: $237.20 million
• Optionable: Not Optionable
• Beta: 1.60